Novavax: ACIP in favour of Covid 24/25 vaccine

(CercleFinance.com) - Novavax reports that the US CDC Advisory Committee on Immunization Practices (ACIP) voted unanimously to recommend universal use of COVID-19 2024-2025 vaccines in persons six months of age and older, a decision approved by the CDC.


Novavax plans to provide its COVID-19 2024-2025 vaccine at the start of the vaccination season, following FDA approval.

This vaccine will be the only protein-based option available for individuals 12 years of age and older. Data show broad neutralization against several variants, including JN.1 and KP.2.

Novavax is working with regulatory authorities to ensure access to its vaccine and has filed applications with the FDA and the European Medicines Agency.


Copyright (c) 2024 CercleFinance.com. All rights reserved.